| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 38 | 2025 | 980 | 8.010 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 13 | 2024 | 47 | 5.960 |
Why?
|
| Genetic Testing | 15 | 2024 | 543 | 4.110 |
Why?
|
| Colon | 9 | 2025 | 521 | 3.330 |
Why?
|
| Carcinoma, Pancreatic Ductal | 5 | 2024 | 120 | 2.610 |
Why?
|
| Celiac Disease | 13 | 2019 | 214 | 2.590 |
Why?
|
| Organoids | 6 | 2025 | 65 | 2.240 |
Why?
|
| Early Detection of Cancer | 11 | 2024 | 422 | 2.230 |
Why?
|
| Calcitriol | 4 | 2021 | 173 | 2.200 |
Why?
|
| Pancreatic Neoplasms | 7 | 2024 | 684 | 2.150 |
Why?
|
| Genetic Predisposition to Disease | 22 | 2024 | 2360 | 1.870 |
Why?
|
| Aspirin | 2 | 2025 | 162 | 1.650 |
Why?
|
| Colonoscopy | 12 | 2023 | 281 | 1.610 |
Why?
|
| Neoplastic Syndromes, Hereditary | 5 | 2024 | 19 | 1.580 |
Why?
|
| Epigenomics | 2 | 2023 | 103 | 1.490 |
Why?
|
| Genetic Counseling | 4 | 2022 | 102 | 1.400 |
Why?
|
| Vitamin D | 7 | 2017 | 269 | 1.340 |
Why?
|
| Humans | 100 | 2025 | 90014 | 1.240 |
Why?
|
| DNA Mismatch Repair | 6 | 2024 | 58 | 1.200 |
Why?
|
| MutL Protein Homolog 1 | 5 | 2024 | 35 | 1.190 |
Why?
|
| Uridine Phosphorylase | 2 | 2018 | 4 | 1.190 |
Why?
|
| Quantitative Trait Loci | 3 | 2025 | 615 | 1.180 |
Why?
|
| Glutens | 6 | 2019 | 84 | 1.150 |
Why?
|
| Heterozygote | 7 | 2024 | 373 | 1.090 |
Why?
|
| Germ-Line Mutation | 7 | 2024 | 347 | 1.060 |
Why?
|
| Middle Aged | 43 | 2025 | 26173 | 1.030 |
Why?
|
| Polymorphism, Single Nucleotide | 10 | 2017 | 2415 | 1.010 |
Why?
|
| Patient Compliance | 2 | 2018 | 230 | 0.970 |
Why?
|
| Gastroenterology | 5 | 2021 | 147 | 0.970 |
Why?
|
| Colonic Polyps | 3 | 2022 | 132 | 0.940 |
Why?
|
| Male | 46 | 2025 | 42705 | 0.900 |
Why?
|
| Aged | 29 | 2025 | 19272 | 0.880 |
Why?
|
| Stomach Neoplasms | 5 | 2024 | 288 | 0.860 |
Why?
|
| Female | 49 | 2025 | 46617 | 0.850 |
Why?
|
| Patient Advocacy | 1 | 2023 | 53 | 0.820 |
Why?
|
| Adenoma | 3 | 2022 | 251 | 0.800 |
Why?
|
| HLA-DQ Antigens | 3 | 2019 | 51 | 0.790 |
Why?
|
| Peutz-Jeghers Syndrome | 1 | 2022 | 9 | 0.790 |
Why?
|
| Glucocorticoids | 2 | 2014 | 358 | 0.760 |
Why?
|
| Risk Factors | 17 | 2024 | 5562 | 0.760 |
Why?
|
| Fellowships and Scholarships | 1 | 2023 | 126 | 0.750 |
Why?
|
| Transcription, Genetic | 3 | 2017 | 1158 | 0.740 |
Why?
|
| Health Policy | 2 | 2021 | 188 | 0.720 |
Why?
|
| Intestine, Small | 3 | 2024 | 299 | 0.710 |
Why?
|
| Adenomatous Polyposis Coli | 4 | 2021 | 39 | 0.710 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2017 | 594 | 0.710 |
Why?
|
| Diet, Gluten-Free | 3 | 2019 | 58 | 0.690 |
Why?
|
| Food Handling | 1 | 2019 | 6 | 0.690 |
Why?
|
| Health Status Disparities | 3 | 2021 | 191 | 0.680 |
Why?
|
| Genomics | 3 | 2025 | 778 | 0.680 |
Why?
|
| Legislation, Medical | 1 | 2019 | 9 | 0.650 |
Why?
|
| BRCA2 Protein | 1 | 2020 | 161 | 0.640 |
Why?
|
| Biomarkers, Tumor | 7 | 2024 | 1545 | 0.630 |
Why?
|
| BRCA1 Protein | 1 | 2020 | 205 | 0.620 |
Why?
|
| Genetic Variation | 4 | 2020 | 1380 | 0.620 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2019 | 163 | 0.610 |
Why?
|
| Uridine | 1 | 2018 | 56 | 0.610 |
Why?
|
| Intestinal Diseases | 1 | 2019 | 79 | 0.610 |
Why?
|
| Colonic Diseases | 1 | 2018 | 61 | 0.590 |
Why?
|
| Transcriptome | 2 | 2021 | 661 | 0.590 |
Why?
|
| Gene Expression Regulation | 3 | 2017 | 1983 | 0.590 |
Why?
|
| Receptors, Calcitriol | 3 | 2018 | 130 | 0.590 |
Why?
|
| Retrospective Studies | 14 | 2024 | 9237 | 0.590 |
Why?
|
| Cell Proliferation | 2 | 2014 | 1670 | 0.590 |
Why?
|
| Medicare | 1 | 2021 | 427 | 0.580 |
Why?
|
| Postoperative Period | 1 | 2018 | 301 | 0.580 |
Why?
|
| United States | 16 | 2023 | 7114 | 0.580 |
Why?
|
| Endometrial Neoplasms | 3 | 2024 | 208 | 0.580 |
Why?
|
| Hematoma | 1 | 2018 | 108 | 0.580 |
Why?
|
| Blood Coagulation Disorders | 1 | 2018 | 66 | 0.570 |
Why?
|
| Biopsy | 8 | 2021 | 1184 | 0.570 |
Why?
|
| Jejunal Neoplasms | 1 | 2017 | 9 | 0.560 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2017 | 11 | 0.560 |
Why?
|
| Cadherins | 4 | 2024 | 163 | 0.550 |
Why?
|
| Adult | 29 | 2024 | 26836 | 0.550 |
Why?
|
| Epithelial Cells | 2 | 2018 | 689 | 0.550 |
Why?
|
| Patient Selection | 3 | 2019 | 682 | 0.550 |
Why?
|
| Practice Guidelines as Topic | 3 | 2021 | 1055 | 0.530 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2019 | 239 | 0.530 |
Why?
|
| DNA Damage | 1 | 2018 | 374 | 0.530 |
Why?
|
| Mass Screening | 2 | 2023 | 647 | 0.520 |
Why?
|
| Breast Neoplasms | 4 | 2024 | 3022 | 0.510 |
Why?
|
| Attitude | 1 | 2016 | 130 | 0.500 |
Why?
|
| Referral and Consultation | 1 | 2018 | 345 | 0.500 |
Why?
|
| Precision Medicine | 1 | 2019 | 413 | 0.490 |
Why?
|
| Antigens, CD | 3 | 2024 | 466 | 0.490 |
Why?
|
| Microsatellite Instability | 5 | 2024 | 53 | 0.470 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2014 | 15 | 0.460 |
Why?
|
| Predictive Value of Tests | 7 | 2020 | 1732 | 0.450 |
Why?
|
| Young Adult | 10 | 2024 | 6418 | 0.440 |
Why?
|
| Family | 1 | 2015 | 324 | 0.430 |
Why?
|
| Genome-Wide Association Study | 6 | 2017 | 1691 | 0.430 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2012 | 83 | 0.420 |
Why?
|
| Adenocarcinoma | 4 | 2024 | 1185 | 0.410 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 206 | 0.410 |
Why?
|
| DNA, Neoplasm | 2 | 2010 | 266 | 0.410 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 784 | 0.410 |
Why?
|
| Diet | 5 | 2021 | 444 | 0.400 |
Why?
|
| Physicians | 2 | 2019 | 692 | 0.400 |
Why?
|
| Polymorphism, Genetic | 2 | 2018 | 824 | 0.390 |
Why?
|
| Time Factors | 8 | 2021 | 5361 | 0.370 |
Why?
|
| Aged, 80 and over | 9 | 2024 | 6787 | 0.370 |
Why?
|
| Incidence | 5 | 2021 | 1604 | 0.350 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2014 | 565 | 0.320 |
Why?
|
| Chromatin | 2 | 2023 | 404 | 0.320 |
Why?
|
| Adaptive Immunity | 3 | 2015 | 167 | 0.320 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 3 | 2019 | 24 | 0.320 |
Why?
|
| Vitamin D3 24-Hydroxylase | 2 | 2021 | 6 | 0.300 |
Why?
|
| Case-Control Studies | 9 | 2024 | 1868 | 0.300 |
Why?
|
| Colitis, Ulcerative | 2 | 2014 | 760 | 0.300 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 1221 | 0.300 |
Why?
|
| Mutation | 3 | 2017 | 4169 | 0.300 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2007 | 14 | 0.300 |
Why?
|
| Mastocytosis | 1 | 2007 | 13 | 0.290 |
Why?
|
| Quality of Life | 1 | 2016 | 1682 | 0.290 |
Why?
|
| Crohn Disease | 1 | 2014 | 764 | 0.290 |
Why?
|
| Risk Assessment | 7 | 2024 | 2327 | 0.290 |
Why?
|
| Vitamins | 2 | 2021 | 83 | 0.290 |
Why?
|
| DNA-Binding Proteins | 6 | 2022 | 1243 | 0.270 |
Why?
|
| Tissue Culture Techniques | 2 | 2018 | 82 | 0.260 |
Why?
|
| DNA Mutational Analysis | 3 | 2021 | 528 | 0.250 |
Why?
|
| Adolescent | 7 | 2024 | 9347 | 0.250 |
Why?
|
| Intestinal Mucosa | 4 | 2019 | 806 | 0.250 |
Why?
|
| Colonic Neoplasms | 4 | 2020 | 572 | 0.250 |
Why?
|
| Inflammation | 4 | 2020 | 981 | 0.240 |
Why?
|
| Anticipation, Genetic | 1 | 2024 | 2 | 0.240 |
Why?
|
| DNA Methylation | 4 | 2020 | 666 | 0.240 |
Why?
|
| Interleukin-15 | 3 | 2015 | 73 | 0.240 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2015 | 313 | 0.230 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2015 | 319 | 0.220 |
Why?
|
| Biomarkers | 3 | 2019 | 1778 | 0.220 |
Why?
|
| Phenotype | 3 | 2020 | 2457 | 0.210 |
Why?
|
| Social Welfare | 1 | 2023 | 19 | 0.210 |
Why?
|
| Perception | 1 | 2024 | 179 | 0.210 |
Why?
|
| Prospective Studies | 4 | 2024 | 4329 | 0.210 |
Why?
|
| Rectal Neoplasms | 1 | 2023 | 129 | 0.200 |
Why?
|
| Age of Onset | 2 | 2021 | 318 | 0.200 |
Why?
|
| Age Factors | 3 | 2020 | 1880 | 0.200 |
Why?
|
| Proportional Hazards Models | 1 | 2024 | 848 | 0.200 |
Why?
|
| Alleles | 2 | 2017 | 1137 | 0.200 |
Why?
|
| Counselors | 1 | 2022 | 6 | 0.200 |
Why?
|
| Chicago | 3 | 2014 | 1434 | 0.200 |
Why?
|
| Intestinal Polyps | 1 | 2022 | 27 | 0.200 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2014 | 182 | 0.200 |
Why?
|
| ErbB Receptors | 2 | 2018 | 499 | 0.200 |
Why?
|
| MicroRNAs | 2 | 2020 | 556 | 0.190 |
Why?
|
| Point-of-Care Systems | 1 | 2023 | 146 | 0.190 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 2658 | 0.190 |
Why?
|
| Mucous Membrane | 1 | 2022 | 83 | 0.190 |
Why?
|
| Text Messaging | 1 | 2022 | 31 | 0.190 |
Why?
|
| MutS Homolog 2 Protein | 3 | 2019 | 33 | 0.190 |
Why?
|
| Gene Frequency | 3 | 2014 | 687 | 0.190 |
Why?
|
| Southeastern United States | 1 | 2021 | 8 | 0.190 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2022 | 131 | 0.190 |
Why?
|
| Occult Blood | 1 | 2021 | 18 | 0.190 |
Why?
|
| Sex Factors | 2 | 2015 | 1075 | 0.190 |
Why?
|
| Delayed Diagnosis | 1 | 2021 | 34 | 0.190 |
Why?
|
| Deoxyribonuclease (Pyrimidine Dimer) | 1 | 2021 | 1 | 0.190 |
Why?
|
| Life Style | 2 | 2023 | 176 | 0.180 |
Why?
|
| Evidence-Based Medicine | 2 | 2021 | 435 | 0.180 |
Why?
|
| Gene-Environment Interaction | 2 | 2012 | 118 | 0.180 |
Why?
|
| Microbiota | 2 | 2017 | 409 | 0.180 |
Why?
|
| Meningioma | 1 | 2021 | 62 | 0.180 |
Why?
|
| Child | 6 | 2024 | 7242 | 0.180 |
Why?
|
| Meningeal Neoplasms | 1 | 2021 | 66 | 0.180 |
Why?
|
| Geography | 1 | 2021 | 227 | 0.180 |
Why?
|
| Immunity, Innate | 2 | 2014 | 434 | 0.180 |
Why?
|
| Chemoprevention | 2 | 2018 | 92 | 0.170 |
Why?
|
| Transcriptional Activation | 1 | 2021 | 294 | 0.170 |
Why?
|
| Treatment Outcome | 6 | 2018 | 8292 | 0.170 |
Why?
|
| Stem Cells | 1 | 2022 | 376 | 0.170 |
Why?
|
| Health Behavior | 1 | 2021 | 185 | 0.170 |
Why?
|
| Antigens | 2 | 2019 | 229 | 0.170 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 1606 | 0.170 |
Why?
|
| Lobbying | 1 | 2019 | 3 | 0.160 |
Why?
|
| Intestinal Absorption | 1 | 2019 | 125 | 0.160 |
Why?
|
| Duodenum | 1 | 2019 | 105 | 0.160 |
Why?
|
| Federal Government | 1 | 2019 | 29 | 0.160 |
Why?
|
| Endoscopy | 1 | 2022 | 352 | 0.160 |
Why?
|
| Food | 1 | 2019 | 89 | 0.160 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 1731 | 0.160 |
Why?
|
| Th1 Cells | 2 | 2017 | 166 | 0.160 |
Why?
|
| Health Surveys | 1 | 2019 | 240 | 0.160 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2018 | 40 | 0.160 |
Why?
|
| Capsule Endoscopy | 1 | 2019 | 33 | 0.160 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2018 | 41 | 0.160 |
Why?
|
| Up-Regulation | 3 | 2020 | 726 | 0.160 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2018 | 26 | 0.160 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 30 | 0.160 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2018 | 72 | 0.150 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2018 | 57 | 0.150 |
Why?
|
| Whipple Disease | 1 | 2018 | 1 | 0.150 |
Why?
|
| Tropheryma | 1 | 2018 | 1 | 0.150 |
Why?
|
| Microsatellite Repeats | 1 | 2018 | 148 | 0.150 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 332 | 0.150 |
Why?
|
| Aberrant Crypt Foci | 1 | 2018 | 7 | 0.150 |
Why?
|
| Cytoprotection | 1 | 2018 | 47 | 0.150 |
Why?
|
| Ileum | 1 | 2019 | 168 | 0.150 |
Why?
|
| Laxatives | 1 | 2018 | 13 | 0.150 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2019 | 105 | 0.150 |
Why?
|
| Apoptosis | 1 | 2025 | 1718 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 2677 | 0.150 |
Why?
|
| Adenomatous Polyps | 1 | 2017 | 13 | 0.150 |
Why?
|
| Colitis | 1 | 2020 | 247 | 0.150 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 1747 | 0.150 |
Why?
|
| Anticarcinogenic Agents | 1 | 2018 | 73 | 0.150 |
Why?
|
| Digestive System Neoplasms | 1 | 2017 | 21 | 0.150 |
Why?
|
| Interferon Type I | 2 | 2017 | 186 | 0.140 |
Why?
|
| Reoviridae Infections | 1 | 2017 | 7 | 0.140 |
Why?
|
| Avena | 1 | 2017 | 19 | 0.140 |
Why?
|
| Transcription Factors | 2 | 2023 | 1665 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 2 | 2018 | 961 | 0.140 |
Why?
|
| Research Support as Topic | 1 | 2017 | 85 | 0.140 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2018 | 217 | 0.140 |
Why?
|
| Colonography, Computed Tomographic | 1 | 2017 | 81 | 0.140 |
Why?
|
| Organ Culture Techniques | 1 | 2017 | 135 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 260 | 0.140 |
Why?
|
| Pharmaceutical Research | 1 | 2016 | 2 | 0.140 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2017 | 125 | 0.140 |
Why?
|
| Drug Monitoring | 1 | 2017 | 118 | 0.140 |
Why?
|
| Drug Evaluation | 1 | 2016 | 137 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 432 | 0.130 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 137 | 0.130 |
Why?
|
| Gastrointestinal Diseases | 1 | 2017 | 151 | 0.130 |
Why?
|
| Drug Approval | 1 | 2016 | 65 | 0.130 |
Why?
|
| Polyethylene Glycols | 1 | 2018 | 360 | 0.130 |
Why?
|
| Leukotrienes | 1 | 2015 | 20 | 0.130 |
Why?
|
| Genotype | 4 | 2017 | 1852 | 0.130 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2015 | 32 | 0.130 |
Why?
|
| Dietary Supplements | 1 | 2016 | 124 | 0.130 |
Why?
|
| Gastrointestinal Agents | 1 | 2017 | 174 | 0.130 |
Why?
|
| Binding Sites | 1 | 2018 | 1122 | 0.130 |
Why?
|
| Overweight | 1 | 2016 | 119 | 0.120 |
Why?
|
| Mice | 6 | 2022 | 11858 | 0.120 |
Why?
|
| DNA Repair Enzymes | 1 | 2015 | 55 | 0.120 |
Why?
|
| Communication | 1 | 2019 | 461 | 0.120 |
Why?
|
| Isotretinoin | 1 | 2014 | 21 | 0.120 |
Why?
|
| Prognosis | 2 | 2020 | 3800 | 0.120 |
Why?
|
| Cysteine | 1 | 2015 | 137 | 0.120 |
Why?
|
| Phytohemagglutinins | 1 | 2014 | 21 | 0.120 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2017 | 346 | 0.120 |
Why?
|
| Adenosine Triphosphatases | 1 | 2015 | 155 | 0.120 |
Why?
|
| Cells, Cultured | 3 | 2015 | 2887 | 0.120 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 437 | 0.120 |
Why?
|
| Smad7 Protein | 1 | 2014 | 7 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2017 | 2887 | 0.120 |
Why?
|
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2014 | 10 | 0.120 |
Why?
|
| Cell Communication | 1 | 2015 | 200 | 0.120 |
Why?
|
| CD3 Complex | 1 | 2014 | 134 | 0.120 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 82 | 0.110 |
Why?
|
| CD28 Antigens | 1 | 2014 | 90 | 0.110 |
Why?
|
| Organ Specificity | 1 | 2015 | 277 | 0.110 |
Why?
|
| Dermatologic Agents | 1 | 2014 | 73 | 0.110 |
Why?
|
| Drug Resistance | 1 | 2014 | 232 | 0.110 |
Why?
|
| Electron Transport | 1 | 2013 | 74 | 0.110 |
Why?
|
| Cell Line | 1 | 2018 | 2495 | 0.110 |
Why?
|
| Societies, Medical | 1 | 2017 | 584 | 0.110 |
Why?
|
| Nuclear Proteins | 2 | 2015 | 728 | 0.110 |
Why?
|
| Kidney Diseases | 1 | 1996 | 320 | 0.110 |
Why?
|
| Stress, Physiological | 1 | 2015 | 232 | 0.110 |
Why?
|
| Drug Synergism | 1 | 2013 | 307 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2017 | 405 | 0.110 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 462 | 0.110 |
Why?
|
| Interleukin-6 | 1 | 2014 | 264 | 0.110 |
Why?
|
| Lipopolysaccharides | 1 | 2014 | 295 | 0.100 |
Why?
|
| Pathology, Clinical | 2 | 2024 | 34 | 0.100 |
Why?
|
| Urban Population | 1 | 2014 | 225 | 0.100 |
Why?
|
| Linkage Disequilibrium | 1 | 2014 | 477 | 0.100 |
Why?
|
| Sex Distribution | 2 | 2017 | 171 | 0.100 |
Why?
|
| Calcium | 1 | 2016 | 1179 | 0.100 |
Why?
|
| Odds Ratio | 2 | 2011 | 682 | 0.100 |
Why?
|
| Genes, myc | 1 | 2012 | 40 | 0.100 |
Why?
|
| Spain | 1 | 2011 | 32 | 0.100 |
Why?
|
| North Carolina | 1 | 2011 | 51 | 0.100 |
Why?
|
| Dexamethasone | 1 | 2013 | 343 | 0.100 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 385 | 0.090 |
Why?
|
| Carrier Proteins | 1 | 2015 | 679 | 0.090 |
Why?
|
| Animals | 7 | 2022 | 27536 | 0.090 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 310 | 0.090 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 1452 | 0.090 |
Why?
|
| Kidney | 1 | 1996 | 1148 | 0.090 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2011 | 154 | 0.090 |
Why?
|
| Introns | 1 | 2011 | 301 | 0.090 |
Why?
|
| Tretinoin | 1 | 2011 | 128 | 0.090 |
Why?
|
| Confidence Intervals | 1 | 2010 | 221 | 0.090 |
Why?
|
| Adjuvants, Immunologic | 1 | 2011 | 169 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 716 | 0.080 |
Why?
|
| Obesity | 1 | 2016 | 972 | 0.080 |
Why?
|
| Europe | 1 | 2010 | 324 | 0.080 |
Why?
|
| Signal Transduction | 3 | 2015 | 3404 | 0.080 |
Why?
|
| Carcinoma | 1 | 2012 | 438 | 0.080 |
Why?
|
| RNA, Messenger | 1 | 2014 | 2026 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2007 | 79 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2007 | 296 | 0.070 |
Why?
|
| Hepatitis B, Chronic | 1 | 2006 | 32 | 0.070 |
Why?
|
| Leukemia, Myeloid | 1 | 2007 | 249 | 0.070 |
Why?
|
| Survival Rate | 1 | 2010 | 1899 | 0.070 |
Why?
|
| Acute Disease | 1 | 2007 | 846 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2020 | 1284 | 0.060 |
Why?
|
| Family Health | 1 | 2006 | 162 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2020 | 521 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2024 | 2770 | 0.060 |
Why?
|
| Penetrance | 1 | 2024 | 45 | 0.060 |
Why?
|
| Loss of Function Mutation | 1 | 2024 | 46 | 0.060 |
Why?
|
| Medical History Taking | 1 | 2024 | 83 | 0.060 |
Why?
|
| HEK293 Cells | 2 | 2019 | 646 | 0.060 |
Why?
|
| Intestinal Neoplasms | 1 | 2024 | 68 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2018 | 665 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2006 | 482 | 0.050 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2022 | 54 | 0.050 |
Why?
|
| Americas | 1 | 2022 | 19 | 0.050 |
Why?
|
| Cathartics | 1 | 2022 | 27 | 0.050 |
Why?
|
| Immune Tolerance | 2 | 2017 | 341 | 0.050 |
Why?
|
| Drug Discovery | 1 | 2022 | 107 | 0.050 |
Why?
|
| Pancreas | 1 | 2023 | 253 | 0.050 |
Why?
|
| Esophageal Neoplasms | 1 | 2024 | 332 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2014 | 667 | 0.050 |
Why?
|
| Karyopherins | 1 | 2020 | 15 | 0.050 |
Why?
|
| Morphogenesis | 1 | 2022 | 207 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2024 | 384 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2017 | 1579 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 1 | 2021 | 149 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 1 | 2021 | 225 | 0.040 |
Why?
|
| Cell Survival | 1 | 2022 | 983 | 0.040 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2020 | 112 | 0.040 |
Why?
|
| Butyrophilins | 1 | 2019 | 22 | 0.040 |
Why?
|
| Intraepithelial Lymphocytes | 1 | 2019 | 16 | 0.040 |
Why?
|
| GATA6 Transcription Factor | 1 | 2018 | 13 | 0.040 |
Why?
|
| SOX9 Transcription Factor | 1 | 2018 | 28 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 490 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 3684 | 0.040 |
Why?
|
| Mixed Function Oxygenases | 1 | 2018 | 69 | 0.040 |
Why?
|
| Placebo Effect | 1 | 2018 | 30 | 0.040 |
Why?
|
| Bacteriological Techniques | 1 | 2018 | 39 | 0.040 |
Why?
|
| Wnt Signaling Pathway | 1 | 2018 | 99 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2022 | 457 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 181 | 0.040 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2017 | 6 | 0.040 |
Why?
|
| Reoviridae | 1 | 2017 | 6 | 0.040 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2017 | 19 | 0.040 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2017 | 20 | 0.040 |
Why?
|
| Rectum | 1 | 2018 | 148 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2017 | 3253 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 110 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2017 | 50 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 2017 | 115 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2017 | 108 | 0.030 |
Why?
|
| Pedigree | 1 | 2018 | 969 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2011 | 3773 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2019 | 395 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 232 | 0.030 |
Why?
|
| Mastectomy | 1 | 2018 | 246 | 0.030 |
Why?
|
| Colectomy | 1 | 2017 | 175 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2017 | 310 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2017 | 161 | 0.030 |
Why?
|
| Hematuria | 1 | 1996 | 50 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2016 | 111 | 0.030 |
Why?
|
| Receptors, Leukotriene | 1 | 2015 | 10 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2018 | 919 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 869 | 0.030 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2015 | 22 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 958 | 0.030 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2015 | 33 | 0.030 |
Why?
|
| Consensus | 1 | 2017 | 366 | 0.030 |
Why?
|
| Transglutaminases | 1 | 2015 | 40 | 0.030 |
Why?
|
| Autophagy-Related Proteins | 1 | 2015 | 21 | 0.030 |
Why?
|
| Italy | 1 | 2015 | 108 | 0.030 |
Why?
|
| Sweden | 1 | 2014 | 40 | 0.030 |
Why?
|
| GTP-Binding Proteins | 1 | 2015 | 145 | 0.030 |
Why?
|
| Molecular Chaperones | 1 | 2015 | 123 | 0.030 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2015 | 115 | 0.030 |
Why?
|
| Cholestanetriol 26-Monooxygenase | 1 | 2014 | 7 | 0.030 |
Why?
|
| Cytochrome P450 Family 2 | 1 | 2014 | 4 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 2015 | 183 | 0.030 |
Why?
|
| Age Distribution | 1 | 2014 | 199 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1714 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2015 | 270 | 0.030 |
Why?
|
| Intestines | 1 | 2017 | 416 | 0.030 |
Why?
|
| ras Proteins | 1 | 2014 | 130 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 1801 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2014 | 147 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 165 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 841 | 0.030 |
Why?
|
| Risk | 1 | 2014 | 657 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2016 | 776 | 0.030 |
Why?
|
| DNA Glycosylases | 1 | 2012 | 25 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 799 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2016 | 906 | 0.030 |
Why?
|
| Smoking | 1 | 2016 | 625 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2024 | 3481 | 0.020 |
Why?
|
| Dextran Sulfate | 1 | 2011 | 69 | 0.020 |
Why?
|
| G1 Phase | 1 | 2011 | 65 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2015 | 1497 | 0.020 |
Why?
|
| Receptors, Interleukin-12 | 1 | 2011 | 9 | 0.020 |
Why?
|
| Azoxymethane | 1 | 2011 | 84 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2011 | 23 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2011 | 156 | 0.020 |
Why?
|
| Gliadin | 1 | 2011 | 17 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1214 | 0.020 |
Why?
|
| Cetuximab | 1 | 2011 | 115 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2011 | 176 | 0.020 |
Why?
|
| Interleukin-23 | 1 | 2011 | 57 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2012 | 515 | 0.020 |
Why?
|
| Hypertension | 1 | 2016 | 747 | 0.020 |
Why?
|
| Interleukin-12 | 1 | 2011 | 111 | 0.020 |
Why?
|
| Seasons | 1 | 2011 | 240 | 0.020 |
Why?
|
| Registries | 1 | 2014 | 808 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2012 | 1048 | 0.020 |
Why?
|
| Transfection | 1 | 2012 | 909 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2011 | 171 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 2395 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 269 | 0.020 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2012 | 284 | 0.020 |
Why?
|
| Kidney Transplantation | 1 | 1996 | 856 | 0.020 |
Why?
|
| Infant | 1 | 1996 | 3189 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 744 | 0.020 |
Why?
|
| ROC Curve | 1 | 2011 | 778 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 2588 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2011 | 1130 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2011 | 312 | 0.020 |
Why?
|
| Research Design | 1 | 2011 | 591 | 0.020 |
Why?
|
| Surgical Equipment | 1 | 1967 | 4 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2011 | 451 | 0.020 |
Why?
|
| Peritoneal Dialysis | 1 | 1967 | 31 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 2018 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2011 | 952 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 1396 | 0.010 |
Why?
|
| Rats | 1 | 2011 | 4048 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 1134 | 0.010 |
Why?
|
| Fluorocarbon Polymers | 1 | 1967 | 3 | 0.000 |
Why?
|
| Catheterization | 1 | 1967 | 237 | 0.000 |
Why?
|